...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >Bevacizumab for ocular neovascular diseases: a systematic review
【24h】

Bevacizumab for ocular neovascular diseases: a systematic review

机译：贝伐单抗治疗眼部新生血管疾病：系统评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT AND OBJECTIVE: Many eye diseases involve increased local levels of vascular endothelial growth factor (VEGF), and there are several therapeutic strategies for them. Thus, the aim of this study was to evaluate the effectiveness and safety of bevacizumab for treating eye diseases involving increased local levels of VEGF, as the assumed pathophysiological mechanism. DATA SOURCES: The following databases were systematically searched for evidence: PubMed, CENTRAL (Cochrane Library), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) and reference lists, without language restrictions. Only randomized controlled trials were included. The primary outcome of interest was visual acuity, irrespective of the evaluation method. DATA SYNTHESIS: A total of 667 eyes in nine randomized trials were included. Meta-analysis showed that the proportion of patients with age-related macular degeneration who presented improvements from baseline regarding best-corrected visual acuity was higher among those treated with bevacizumab than among those in the photodynamic therapy group (risk ratio, RR, 0.49; 95% confidence interval, CI, 0.31 to 0.78; P = 0.01). CONCLUSIONS: The evidence available demonstrates that bevacizumab alone or combined with other treatments is more effective than other options, including photodynamic therapy, focal photocoagulation and triamcinolone. The use of bevacizumab instead of photodynamic therapy could reduce treatment costs by more than 99% and could significantly increase access to treatment. However, long-term studies are still needed in order to reduce uncertainty concerning the safety of this medication for all ocular neovascular diseases in which bevacizumab has the potential to improve visual acuity.
机译：背景与目的：许多眼部疾病涉及局部增加的血管内皮生长因子（VEGF），有几种治疗策略。因此，本研究的目的是评估贝伐单抗作为一种可能的病理生理机制，用于治疗涉及局部VEGF水平升高的眼部疾病的有效性和安全性。数据来源：系统地搜索了以下数据库以寻找证据：PubMed，CENTRAL（库克兰图书馆），Lateratura Latina-Americana e do Caribe emCiênciasdaSaúde（丁香花）和参考文献列表，没有语言限制。仅包括随机对照试验。不管评估方法如何，关注的主要结果是视敏度。数据综合：包括九项随机试验中的总共667只眼睛。荟萃分析显示，贝伐单抗治疗组的年龄相关性黄斑变性患者在最佳矫正视力方面较基线出现改善的比例高于光动力治疗组（风险比，RR，0.49; 95） ％置信区间CI为0.31至0.78; P = 0.01）。结论：现有证据表明，贝伐单抗单独或与其他疗法联合使用比其他选择更为有效，包括光动力疗法，局部光凝和曲安西龙。使用贝伐单抗代替光动力疗法可将治疗成本降低99％以上，并可显着增加获得治疗的机会。但是，仍然需要进行长期研究，以减少这种药物对贝伐单抗具有改善视敏度潜力的所有眼部新生血管疾病安全性的不确定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号